Multivariable analysis of hypertension (HTN) status as a predictor for progression-free and overall survival (post-cycle 1, day 1) *
| Variable | Progression-free survival | Overall survival | ||||||
| Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | |||||
| HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | |
| Treatment-induced HTN (yes vs no) | 0.241 (0.180 to 0.323) | <.001 | 0.553 (0.443 to 0.690) | <.001 | 0.284 (0.216 to 0.374) | <.001 | 0.516 (0.408 to 0.651) | <.001 |
| Age (<65 vs ≥65 y) | — | — | 1.353 (1.083 to 1.690) | .008 | — | — | — | — |
| ECOG PS (0 vs 1 or 2) ‡ | 0.786 (0.636 to 0.971) | .026 | 0.763 (0.616 to 0.945) | .013 | 0.606 (0.478 to 0.767) | <.001 | 0.616 (0.486 to 0.781) | <.001 |
| Time from diagnosis to treatment ‡ (<1 vs ≥1 y) | 1.308 (1.068 to 1.601) | .009 | 1.290 (1.052 to 1.582) | .014 | 1.687 (1.342 to 2.121) | <.001 | 1.631 (1.298 to 2.050) | <.001 |
| LDH (>1.5 × ULN vs ≤1.5 × ULN) ‡ | 1.751 (1.092 to 2.808) | .020 | 1.703 (1.057 to 2.742) | .029 | 1.686 (1.029 to 2.763) | .038 | 1.796 (1.106 to 2.917) | .018 |
| Platelet count (>ULN vs ≤ULN) | 2.182 (1.586 to 3.000) | <.001 | 2.266 (1.650 to 3.111) | <.001 | 2.035 (1.486 to 2.787) | <.001 | 2.283 (1.673 to 3.116) | <.001 |
| Corrected calcium ‡ (>10 vs ≤10 mg/dL) | — | — | — | — | 1.938 (1.288 to 2.916) | .002 | 1.890 (1.253 to 2.852) | .002 |
| Anti-HTN drug at baseline (yes vs no) | — | — | — | — | 0.755 (0.592 to 0.963) | .024 | 0.725 (0.570 to 0.922) | .009 |
| Variable | Progression-free survival | Overall survival | ||||||
| Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | |||||
| HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | |
| Treatment-induced HTN (yes vs no) | 0.241 (0.180 to 0.323) | <.001 | 0.553 (0.443 to 0.690) | <.001 | 0.284 (0.216 to 0.374) | <.001 | 0.516 (0.408 to 0.651) | <.001 |
| Age (<65 vs ≥65 y) | — | — | 1.353 (1.083 to 1.690) | .008 | — | — | — | — |
| ECOG PS (0 vs 1 or 2) ‡ | 0.786 (0.636 to 0.971) | .026 | 0.763 (0.616 to 0.945) | .013 | 0.606 (0.478 to 0.767) | <.001 | 0.616 (0.486 to 0.781) | <.001 |
| Time from diagnosis to treatment ‡ (<1 vs ≥1 y) | 1.308 (1.068 to 1.601) | .009 | 1.290 (1.052 to 1.582) | .014 | 1.687 (1.342 to 2.121) | <.001 | 1.631 (1.298 to 2.050) | <.001 |
| LDH (>1.5 × ULN vs ≤1.5 × ULN) ‡ | 1.751 (1.092 to 2.808) | .020 | 1.703 (1.057 to 2.742) | .029 | 1.686 (1.029 to 2.763) | .038 | 1.796 (1.106 to 2.917) | .018 |
| Platelet count (>ULN vs ≤ULN) | 2.182 (1.586 to 3.000) | <.001 | 2.266 (1.650 to 3.111) | <.001 | 2.035 (1.486 to 2.787) | <.001 | 2.283 (1.673 to 3.116) | <.001 |
| Corrected calcium ‡ (>10 vs ≤10 mg/dL) | — | — | — | — | 1.938 (1.288 to 2.916) | .002 | 1.890 (1.253 to 2.852) | .002 |
| Anti-HTN drug at baseline (yes vs no) | — | — | — | — | 0.755 (0.592 to 0.963) | .024 | 0.725 (0.570 to 0.922) | .009 |
Hypertension was defined as a maximum SBP of at least 140 mm Hg or a maximum DBP of at least 90 mm Hg. For binary variables, a hazard ratio less than 1 represents risk reduction for the first category and a hazard ratio greater than 1 represents risk reduction for the second category. CI = confidence interval; DBP = diastolic blood pressure; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; LDH = lactate dehydrogenase; SBP = systolic blood pressure; ULN = upper limit of normal.
P values are from a two-sided log-rank test.
Prognostic factors included in Memorial Sloan-Kettering Cancer Center risk-group stratification ( 24 ).
Multivariable analysis of hypertension (HTN) status as a predictor for progression-free and overall survival (post-cycle 1, day 1) *
| Variable | Progression-free survival | Overall survival | ||||||
| Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | |||||
| HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | |
| Treatment-induced HTN (yes vs no) | 0.241 (0.180 to 0.323) | <.001 | 0.553 (0.443 to 0.690) | <.001 | 0.284 (0.216 to 0.374) | <.001 | 0.516 (0.408 to 0.651) | <.001 |
| Age (<65 vs ≥65 y) | — | — | 1.353 (1.083 to 1.690) | .008 | — | — | — | — |
| ECOG PS (0 vs 1 or 2) ‡ | 0.786 (0.636 to 0.971) | .026 | 0.763 (0.616 to 0.945) | .013 | 0.606 (0.478 to 0.767) | <.001 | 0.616 (0.486 to 0.781) | <.001 |
| Time from diagnosis to treatment ‡ (<1 vs ≥1 y) | 1.308 (1.068 to 1.601) | .009 | 1.290 (1.052 to 1.582) | .014 | 1.687 (1.342 to 2.121) | <.001 | 1.631 (1.298 to 2.050) | <.001 |
| LDH (>1.5 × ULN vs ≤1.5 × ULN) ‡ | 1.751 (1.092 to 2.808) | .020 | 1.703 (1.057 to 2.742) | .029 | 1.686 (1.029 to 2.763) | .038 | 1.796 (1.106 to 2.917) | .018 |
| Platelet count (>ULN vs ≤ULN) | 2.182 (1.586 to 3.000) | <.001 | 2.266 (1.650 to 3.111) | <.001 | 2.035 (1.486 to 2.787) | <.001 | 2.283 (1.673 to 3.116) | <.001 |
| Corrected calcium ‡ (>10 vs ≤10 mg/dL) | — | — | — | — | 1.938 (1.288 to 2.916) | .002 | 1.890 (1.253 to 2.852) | .002 |
| Anti-HTN drug at baseline (yes vs no) | — | — | — | — | 0.755 (0.592 to 0.963) | .024 | 0.725 (0.570 to 0.922) | .009 |
| Variable | Progression-free survival | Overall survival | ||||||
| Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | Maximum SBP ≥140 mm Hg (n = 442) vs <140 mm Hg (n = 92) | Maximum DBP ≥90 mm Hg (n = 363) vs <90 mm Hg (n = 171) | |||||
| HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | HR (95% CI) | P† | |
| Treatment-induced HTN (yes vs no) | 0.241 (0.180 to 0.323) | <.001 | 0.553 (0.443 to 0.690) | <.001 | 0.284 (0.216 to 0.374) | <.001 | 0.516 (0.408 to 0.651) | <.001 |
| Age (<65 vs ≥65 y) | — | — | 1.353 (1.083 to 1.690) | .008 | — | — | — | — |
| ECOG PS (0 vs 1 or 2) ‡ | 0.786 (0.636 to 0.971) | .026 | 0.763 (0.616 to 0.945) | .013 | 0.606 (0.478 to 0.767) | <.001 | 0.616 (0.486 to 0.781) | <.001 |
| Time from diagnosis to treatment ‡ (<1 vs ≥1 y) | 1.308 (1.068 to 1.601) | .009 | 1.290 (1.052 to 1.582) | .014 | 1.687 (1.342 to 2.121) | <.001 | 1.631 (1.298 to 2.050) | <.001 |
| LDH (>1.5 × ULN vs ≤1.5 × ULN) ‡ | 1.751 (1.092 to 2.808) | .020 | 1.703 (1.057 to 2.742) | .029 | 1.686 (1.029 to 2.763) | .038 | 1.796 (1.106 to 2.917) | .018 |
| Platelet count (>ULN vs ≤ULN) | 2.182 (1.586 to 3.000) | <.001 | 2.266 (1.650 to 3.111) | <.001 | 2.035 (1.486 to 2.787) | <.001 | 2.283 (1.673 to 3.116) | <.001 |
| Corrected calcium ‡ (>10 vs ≤10 mg/dL) | — | — | — | — | 1.938 (1.288 to 2.916) | .002 | 1.890 (1.253 to 2.852) | .002 |
| Anti-HTN drug at baseline (yes vs no) | — | — | — | — | 0.755 (0.592 to 0.963) | .024 | 0.725 (0.570 to 0.922) | .009 |
Hypertension was defined as a maximum SBP of at least 140 mm Hg or a maximum DBP of at least 90 mm Hg. For binary variables, a hazard ratio less than 1 represents risk reduction for the first category and a hazard ratio greater than 1 represents risk reduction for the second category. CI = confidence interval; DBP = diastolic blood pressure; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; LDH = lactate dehydrogenase; SBP = systolic blood pressure; ULN = upper limit of normal.
P values are from a two-sided log-rank test.
Prognostic factors included in Memorial Sloan-Kettering Cancer Center risk-group stratification ( 24 ).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
